<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8" />
    <title>Elisence — Phase 13: Voice & Zero-Typing Engine</title>
    <meta name="viewport" content="width=device-width, initial-scale=1" />
    <meta
        name="description"
        content="Elisence Phase 13 — Voice and zero-typing engine that lets users talk to Elisence safely in five languages, with strict non-diagnostic, Zero-Trust rules."
    />

    <style>
        :root {
            --bg-dark: #050814;
            --bg-card: #0d1020;
            --accent: #4ea8ff;
            --accent-soft: rgba(78, 168, 255, 0.1);
            --text-main: #f5f7ff;
            --text-muted: #a3b0d8;
            --border-soft: rgba(255, 255, 255, 0.08);
            --danger: #ff5c7a;
            --success: #4fd1c5;
        }

        * {
            box-sizing: border-box;
        }

        body {
            margin: 0;
            font-family: system-ui, -apple-system, BlinkMacSystemFont, "SF Pro Text",
                "Segoe UI", sans-serif;
            background: radial-gradient(circle at top, #111633 0, #050814 60%);
            color: var(--text-main);
            line-height: 1.6;
        }

        a {
            color: var(--accent);
            text-decoration: none;
        }

        a:hover {
            text-decoration: underline;
        }

        header {
            border-bottom: 1px solid var(--border-soft);
            background: linear-gradient(
                to right,
                rgba(7, 12, 40, 0.95),
                rgba(6, 10, 32, 0.98)
            );
            backdrop-filter: blur(14px);
            position: sticky;
            top: 0;
            z-index: 50;
        }

        .nav-shell {
            max-width: 1120px;
            margin: 0 auto;
            padding: 0.75rem 1.5rem;
            display: flex;
            align-items: center;
            justify-content: space-between;
        }

        .brand {
            display: flex;
            align-items: center;
            gap: 0.6rem;
        }

        .brand-logo {
            width: 40px;
            height: 40px;
            border-radius: 999px;
            background: radial-gradient(circle at 30% 20%, #4ea8ff, #7f5dff 45%, #111631);
            box-shadow: 0 0 18px rgba(78, 168, 255, 0.6);
        }

        .brand-text {
            display: flex;
            flex-direction: column;
        }

        .brand-text span:first-child {
            font-weight: 600;
            letter-spacing: 0.08em;
            font-size: 0.8rem;
            text-transform: uppercase;
        }

        .brand-text span:last-child {
            font-size: 0.75rem;
            color: var(--text-muted);
        }

        nav {
            display: flex;
            gap: 1.25rem;
            font-size: 0.9rem;
        }

        nav a {
            color: var(--text-muted);
            padding-bottom: 0.15rem;
            border-bottom: 2px solid transparent;
        }

        nav a:hover {
            color: var(--text-main);
        }

        nav a.active {
            color: var(--accent);
            border-bottom-color: var(--accent);
        }

        main {
            max-width: 1120px;
            margin: 0 auto;
            padding: 2rem 1.5rem 3rem;
        }

        .phase-tag {
            display: inline-flex;
            align-items: center;
            gap: 0.4rem;
            font-size: 0.75rem;
            text-transform: uppercase;
            letter-spacing: 0.12em;
            color: var(--accent);
            background: var(--accent-soft);
            border-radius: 999px;
            padding: 0.35rem 0.9rem;
            border: 1px solid rgba(78, 168, 255, 0.5);
        }

        .phase-tag-dot {
            width: 7px;
            height: 7px;
            border-radius: 999px;
            background: var(--accent);
        }

        h1 {
            margin-top: 1.1rem;
            font-size: 2rem;
            letter-spacing: 0.03em;
        }

        .subtitle {
            margin-top: 0.5rem;
            max-width: 720px;
            color: var(--text-muted);
            font-size: 0.98rem;
        }

        .grid {
            margin-top: 2rem;
            display: grid;
            grid-template-columns: minmax(0, 3fr) minmax(0, 2fr);
            gap: 1.75rem;
        }

        @media (max-width: 900px) {
            .grid {
                grid-template-columns: minmax(0, 1fr);
            }

            nav {
                display: none; /* simple mobile version for now */
            }

            header {
                position: static;
            }
        }

        .card {
            background: radial-gradient(circle at top left, #1a2147 0, #090d20 55%);
            border-radius: 1.25rem;
            border: 1px solid var(--border-soft);
            padding: 1.5rem 1.4rem;
            box-shadow: 0 24px 60px rgba(0, 0, 0, 0.4);
        }

        .card h2 {
            margin-top: 0;
            font-size: 1.1rem;
            letter-spacing: 0.08em;
            text-transform: uppercase;
            color: var(--text-muted);
        }

        .card h3 {
            margin-top: 1.3rem;
            font-size: 1rem;
        }

        .pill-list {
            display: flex;
            flex-wrap: wrap;
            gap: 0.45rem;
            margin-top: 0.75rem;
            margin-bottom: 0.25rem;
        }

        .pill {
            font-size: 0.78rem;
            padding: 0.28rem 0.7rem;
            border-radius: 999px;
            border: 1px solid var(--border-soft);
            background: rgba(10, 15, 40, 0.9);
            color: var(--text-muted);
            white-space: nowrap;
        }

        .pill.pill-strong {
            border-color: var(--accent);
            color: var(--accent);
            background: var(--accent-soft);
        }

        .badge-row {
            display: flex;
            flex-wrap: wrap;
            gap: 0.4rem;
            margin-top: 0.8rem;
        }

        .badge {
            font-size: 0.72rem;
            padding: 0.22rem 0.55rem;
            border-radius: 0.4rem;
            border: 1px solid var(--border-soft);
            color: var(--text-muted);
        }

        .badge.badge-safe {
            border-color: var(--success);
            color: var(--success);
        }

        .badge.badge-risk {
            border-color: var(--danger);
            color: var(--danger);
        }

        .section {
            margin-top: 2rem;
        }

        .section h2 {
            font-size: 1.05rem;
            text-transform: uppercase;
            letter-spacing: 0.13em;
            color: var(--text-muted);
            margin-bottom: 0.3rem;
        }

        .section h3 {
            font-size: 1rem;
            margin-top: 1.1rem;
            margin-bottom: 0.2rem;
        }

        .section p {
            font-size: 0.95rem;
            color: var(--text-main);
        }

        .section ul {
            margin: 0.5rem 0 0.5rem 1.2rem;
            padding-left: 0;
            font-size: 0.93rem;
            color: var(--text-muted);
        }

        .section li {
            margin-bottom: 0.25rem;
        }

        .footer-note {
            margin-top: 2.5rem;
            padding-top: 1.2rem;
            border-top: 1px solid var(--border-soft);
            font-size: 0.86rem;
            color: var(--text-muted);
        }

        .highlight {
            color: var(--accent);
            font-weight: 500;
        }
    </style>
<header>
    <div class="header-inner">
        <div class="logo-section">
            <img src="elisence.png" alt="Elisence Logo" class="logo-img">
            <div class="logo-text">
                <h1>ELISENCE</h1>
                <p>Global Digital Health & Humanity Platform</p>
            </div>
        </div>

        <nav class="main-nav">
            <a href="index.html">Home</a>
            <a href="index.html#phases">Phases</a>
            <a href="about.html">About</a>
            <a href="story.html">Story</a>
            <a href="video.html">Videos</a>
            <a href="contact.html">Contact</a>
        </nav>
    </div>
</header>

<main>
    <div class="phase-tag">
        <span class="phase-tag-dot"></span>
        <span>Phase 13 &mdash; Voice &amp; Zero-Typing Engine</span>
    </div>

    <h1>Talking to Elisence, Safely, in Five Languages</h1>
    <p class="subtitle">
        Phase 13 is the voice and zero-typing layer of Elisence. It lets people talk to Elisa
        in natural language, while keeping every step non-diagnostic, auditable and safe for
        real-world health journeys across English, Farsi, Arabic, Turkish and Romanian.
    </p>

    <div class="grid">
        <section class="card">
            <h2>Core Definition</h2>
            <h3>What Phase 13 Is</h3>
            <p>
                Phase 13 is Elisence’s <span class="highlight">Voice &amp; Zero-Typing Engine</span>.
                It turns speech into safe actions, so users can say:
            </p>
            <ul>
                <li>“Elisa, show me my diabetes dashboard.”</li>
                <li>“My bleeding is very heavy and I feel dizzy.”</li>
                <li>“Read this medicine label for me.”</li>
                <li>“Take me to Women’s pain information.”</li>
            </ul>
            <p>
                The engine converts voice to text, text to intent, and intent to
                <span class="highlight">governed, non-diagnostic responses</span>.
            </p>

            <h3>Design Principles</h3>
            <div class="pill-list">
                <span class="pill pill-strong">Zero-Trust by default</span>
                <span class="pill pill-strong">Non-diagnostic, non-prescriptive</span>
                <span class="pill">NHS / EU MDR / FDA CDS boundary-aware</span>
                <span class="pill">5-language, accent-aware foundation</span>
                <span class="pill">BBVP: Build, Back, Verify, Prove</span>
            </div>
        </section>

        <aside class="card">
            <h2>Stakeholder View</h2>
            <h3>Who Benefits From Phase 13?</h3>
            <ul>
                <li>Citizens who prefer speaking instead of typing</li>
                <li>Women+ users describing symptoms in their own words</li>
                <li>People living with diabetes or chronic conditions</li>
                <li>Blind and low-vision users needing voice-first access</li>
                <li>Clinicians and ministries that want safe, auditable voice flows</li>
            </ul>

            <h3>Safety Guarantees</h3>
            <div class="badge-row">
                <span class="badge badge-safe">No diagnosis, ever</span>
                <span class="badge badge-safe">No dosage or treatment decisions</span>
                <span class="badge badge-safe">Uncertainty = clarify or safe fallback</span>
                <span class="badge badge-safe">WORM audit for safety events</span>
                <span class="badge badge-risk">No “It is safe / unsafe to cross”</span>
                <span class="badge badge-risk">No navigation decisions</span>
            </div>
        </aside>
    </div>

    <section class="section">
        <h2>How the Voice Engine Works</h2>
        <h3>From Speech to Safe Action</h3>
        <p>
            Phase 13 follows a clear, inspectable pipeline:
        </p>
        <ul>
            <li><strong>Audio capture</strong> on the phone or headset</li>
            <li><strong>Speech-to-text</strong> (on-device where possible, edge or cloud as backup)</li>
            <li><strong>Intent extraction</strong> using hybrid rules and models</li>
            <li><strong>Safety guard</strong> checking symptoms, roles and country rules</li>
            <li><strong>Routing</strong> to Women+, Diabetes, AHE, Blind-Assist or coaching engines</li>
            <li><strong>Localized response</strong> in the user’s language, text and voice</li>
            <li><strong>WORM logging</strong> for safety-relevant decisions</li>
        </ul>
        <p>
            Each step is testable and traceable. Phase 13 is not a black-box assistant;
            it is a governed control layer on top of Elisence’s health engines.
        </p>
    </section>

    <section class="section">
        <h2>Noise, Reliability &amp; Uncertainty</h2>
        <h3>Built for Real Homes and Hospitals</h3>
        <p>
            Voice systems often break in noisy, stressful environments. Phase 13 treats this as a
            first-class problem, not an afterthought:
        </p>
        <ul>
            <li>Uses more than one STT source when allowed, and compares meanings</li>
            <li>Flags inputs as <em>uncertain</em> when transcripts do not agree</li>
            <li>Never silently guesses around safety-related words</li>
        </ul>
        <p>
            When uncertainty is detected around symptoms like heavy bleeding, chest pain or severe
            dizziness, Elisa will ask for clarification rather than acting as if she is sure.
            If doubt remains, the system falls back to generic, guideline-safe advice such as
            seeking urgent care, instead of making a risky decision.
        </p>
    </section>

    <section class="section">
        <h2>Accents, Dialects &amp; Five Languages</h2>
        <h3>Accent-Aware, Not Accent-Blind</h3>
        <p>
            Phase 13 is designed for English, Farsi, Arabic, Turkish and Romanian, with space for
            multiple accents and dialects within each language. Every session carries:
        </p>
        <ul>
            <li>a language code (en, fa, ar, tr, ro)</li>
            <li>a region hint (UK, EU, GCC and others)</li>
            <li>an accent hint where available (for example Gulf Arabic vs other variants)</li>
        </ul>
        <p>
            Vocabulary is hybrid: shared clinical and wellness terms plus regional phrases, with
            conservative behaviour when confidence is low. The engine prefers to admit uncertainty
            rather than pretend it understands every accent perfectly from day one.
        </p>
    </section>

    <section class="section">
        <h2>Non-Medical, Non-Diagnostic Boundary</h2>
        <h3>Voice as a Companion, Not a Doctor</h3>
        <p>
            Even when users describe serious symptoms, Phase 13 is carefully positioned as a
            <span class="highlight">wellness and guidance companion</span>, not a diagnostic tool:
        </p>
        <ul>
            <li>No statements like “You have anaemia” or “You are having a stroke”</li>
            <li>No direct dosage or medication decisions</li>
            <li>No replacement of clinicians or emergency services</li>
        </ul>
        <p>
            Instead, the engine recognises categories of concern and delivers general, legally safe
            guidance, encouraging users to seek proper care when needed. This keeps Elisence on the
            safe side of NHS, FDA CDS, EU MDR and GCC rules.
        </p>
    </section>

    <section class="section">
        <h2>Blind-Assist &amp; Accessibility</h2>
        <h3>Describing the World, Not Controlling It</h3>
        <p>
            Together with the accessibility phases, Phase 13 acts as the voice of Elisence for blind
            and low-vision users:
        </p>
        <ul>
            <li>Reading medicine labels, menus and signs aloud</li>
            <li>Describing scenes in front of the camera in soft language (“It looks like…”, “There may be…”) </li>
            <li>Helping users move through Elisence without typing or complex gestures</li>
        </ul>
        <p>
            It deliberately avoids giving precise navigation commands or promises of safety.
            Existing mobility tools remain in charge; Elisence’s role is to describe, not to direct.
        </p>
    </section>

    <section class="section">
        <h2>Latency, Performance &amp; Cost</h2>
        <h3>Fast Enough to Feel Human</h3>
        <p>
            To feel natural, voice needs to respond quickly. Phase 13 is engineered with strict
            latency budgets:
        </p>
        <ul>
            <li>On-device speech recognition where possible</li>
            <li>Lightweight intent and safety checks</li>
            <li>Streaming voice responses so users hear the first words in under a second in typical conditions</li>
        </ul>
        <p>
            On-device and edge processing keep both latency and cost under control, so voice can
            scale to national programmes without becoming unaffordable.
        </p>
    </section>

    <section class="section">
        <h2>Security, Zero-Trust &amp; Audit</h2>
        <h3>Every Utterance Under Control</h3>
        <p>
            Phase 13 inherits the security spine of Elisence:
        </p>
        <ul>
            <li>Every request is tied to a Phase 11 passport and role</li>
            <li>Actions are constrained by scopes and jurisdiction rules</li>
            <li>Safety-critical events are logged in append-only WORM audit trails</li>
        </ul>
        <p>
            This means regulators and ministries can see, in detail, how voice inputs were
            interpreted, which rules fired and why certain responses were given.
        </p>
    </section>

    <section class="section">
        <h2>Integration With Other Phases</h2>
        <h3>Voice Front Door for All Journeys</h3>
        <p>
            Phase 13 does not work in isolation. It is the voice front door for:
        </p>
        <ul>
            <li>Women+ health journeys (Phase 7)</li>
            <li>Diabetes and metabolic health (Phase 9)</li>
            <li>Social profiles and messages (Phase 10)</li>
            <li>Security and passports (Phase 11)</li>
            <li>Real-time calls (Phase 12)</li>
            <li>Accessibility and mental health phases beyond</li>
        </ul>
        <p>
            In practice, it lets people say what they need, in their own words, and then hands off
            to the right engine under clear, auditable rules.
        </p>
    </section>

    <section class="section">
        <h2>Government &amp; Investor View</h2>
        <h3>Accessible, Yet Legally Defensible</h3>
        <p>
            For governments and health systems, Phase 13 offers voice access without creating
            unmanaged risk:
        </p>
        <ul>
            <li>Clear non-diagnostic boundary</li>
            <li>Evidence-based validation and stress testing</li>
            <li>Transparent metrics on accuracy, latency and safety fallbacks</li>
        </ul>
        <p>
            For investors, it turns Elisence from a “text app” into a genuinely inclusive companion
            that people can speak to, in their own language and accent, while still satisfying strict
            regulatory expectations.
        </p>
    </section>

    <div class="footer-note">
        <strong>In one sentence:</strong>
        Phase 13 makes Elisence a <span class="highlight">true voice-first health companion</span> &mdash;
        people talk, Elisa listens and responds safely, in five languages, under a Zero-Trust,
        non-diagnostic architecture that regulators and investors can understand and trust.
    </div>
</main>
</body>
</html>
